HALO News and Press, Halozyme Therapeutics Inc. From 09/23/20

Genmab (GMAB) down 12% premarket in reaction to the announcement that it was locked in a legal battle with its partner Johnson & Johnson (JNJ) over royalty payments for its key cancer drug, source Reuters.Yesterday, GMAB commenced binding arbitration of two matters under license...

SAN DIEGO , Sept. 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq ® ) for subcutaneous administ...

SAN DIEGO , Sept. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approva...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference. Dr. Torley will take part in a fireside cha...

Due to the S&P 500's 66% rally since the March lows, many stocks are expensive and overextended. Investors should consider investing in value stocks to balance their portfolios. EGO, HALO, and BSIG are three high-quality value stocks that will outperform in the months ahead. Given the ...

Image source: The Motley Fool. Halozyme Therapeutics Inc   (NASDAQ: HALO) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading

Halozyme Therapeutics, Inc. (HALO) Q2 2020 Earnings Conference Call August 10, 2020 4:30 PM ET Company Participants Al Kildani – Vice President-Investor Relations and Corporate Communications Helen Torley – President and Chief Executive Officer Elaine Sun – C...

SAN DIEGO , Aug. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2020 and provided an update on its recent corporate activities and outlook. "The second quarter marked the achievement of mult...

Halozyme Therapeutics (NASDAQ: HALO ) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. The consensus EPS Estimate is $0.24  vs. -$0.10 in 2Q19 and the consensus Revenue Estimate is $65.81M (+68.1% Y/Y). Over the last 2 years, HALO has beaten...